EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Early improvement with cariprazine as a predictor of antidepressant, anxiolytic, and antimanic response in bipolar I mania and depression: A pooled post hoc analysis of randomized cariprazine trials

Mauricio Tohen, Jun Yu, Ken Kramer, Huy-Binh Nguyen

Journal of Affective Disorders · 2024

DOI: 10.1016/j.jad.2024.06.100 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2024. Verfasst von Mauricio Tohen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque, NM, USA. Hauptthemen laut MEDLINE: Bipolar Disorder, Piperazines, Antidepressive Agents, Antimanic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Early symptomatic improvement may predict treatment response in bipolar I disorder. Cariprazine has demonstrated early treatment effects in bipolar I depression and mania studies; therefore, we assessed whether early improvement with cariprazine predicts eventual treatment response. METHODS: Post hoc analyses used pooled data from randomized, double-blind, placebo-controlled bipolar I depression (NCT02670538, NCT02670551) and mania (NCT00488618, NCT01058096, NCT01058668) trials. In depression studies (cariprazine 1.5 mg/d, 3 mg/d, or placebo), early improvement in Montgomery-Åsberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A) total scores (≥25 % improvement at day 15) and subsequent depressive/anxiety symptom response status (≥50 % improvement at week 6) were assessed. In mania studies (cariprazine 3-12 mg/d or placebo), early improvement in Young Mania Rating Scale (YMRS) total scores (≥25 % improvement at day 7) and manic symptom response status (≥50 % improvement at week 3) were assessed. RESULTS: Patients with bipolar I depression and early MADRS improvement were approximately 4- to 6-times as likely to achieve MADRS or HAM-A response than those without early improvement; patients with early HAM-A improvement were approximately 3- to 4-times as likely to achieve MADRS or HAM-A response. A subset of patients without early improvement with cariprazine 1.5 mg/d (20 %-31 %) subsequently responded following up-titration. Patients with mania and early YMRS improvement were approximately 5 times more likely to have manic symptom response than those without early improvement. LIMITATIONS: Post hoc analysis; relatively short study durations; flexible-dosing (mania studies). CONCLUSIONS: Early symptom improvement with cariprazine may inform therapeutic decisions for patients with bipolar I disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderPiperazinesAntidepressive AgentsAntimanic AgentsAnti-Anxiety AgentsHumansMaleFemaleAdultDouble-Blind MethodMiddle AgedManiaTreatment OutcomePsychiatric Status Rating Scales

Stichwörter der Autor:innen

Bipolar I depressionBipolar I disorderBipolar I maniaCariprazineEarly improvementPredictor analysis

Substanzen

cariprazinePiperazinesAntidepressive AgentsAntimanic AgentsAnti-Anxiety Agents

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque, NM, USA.
  • AbbVie, Florham Park, NJ, USA.
  • AbbVie, Florham Park, NJ, USA. Electronic address: binh.nguyen@abbvie.com.

Förderung

  • AbbVie Inc

Zitieren

APA

Tohen, M., Yu, J., Kramer, K., & Nguyen, H. B. (2024). Early improvement with cariprazine as a predictor of antidepressant, anxiolytic, and antimanic response in bipolar I mania and depression: A pooled post hoc analysis of randomized cariprazine trials. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.06.100

Vancouver

Tohen M, Yu J, Kramer K, Nguyen HB. Early improvement with cariprazine as a predictor of antidepressant, anxiolytic, and antimanic response in bipolar I mania and depression: A pooled post hoc analysis of randomized cariprazine trials. Journal of Affective Disorders. 2024. doi:10.1016/j.jad.2024.06.100

BibTeX
@article{Tohen2024,
  author = {Tohen, Mauricio and Yu, Jun and Kramer, Ken and Nguyen, Huy-Binh},
  title = {Early improvement with cariprazine as a predictor of antidepressant, anxiolytic, and antimanic response in bipolar I mania and depression: A pooled post hoc analysis of randomized cariprazine trials},
  journal = {Journal of Affective Disorders},
  year = {2024},
  doi = {10.1016/j.jad.2024.06.100}
}
Kostenlos starten →